MAPK7 and cancer: SKLB-D18 has achieved precise regulation of multiple signaling pathways in the form of a single molecule, demonstrating significant anti-TNBC activity, providing theoretical and experimental support for the potential application of single-molecule targeting of the ERK5 compensatory mechanism in cancer therapy.